KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer

摘要

Background:KRAS mutations are predictive markers for the efficacy of anti-EGFR antibody therapies in patients with metastatic colorectal cancer. Although the mutational status of KRAS is reportedly highly concordant between primary and metastatic lesions, it is not yet clear whether genotoxic chemotherapies might induce additional mutations.